




COMMON POSITION ON UNGASS 2016 
 
 
UNGASS 2016 is a key opportunity for the international community to take stock of the 
achievements of the international drug control system to date, to elaborate on the 
immense challenges that remain in the global, national and local response to the world 
drug problem and to find feasible, operational and sustainable solutions for the longer 
term within the framework of the international treaties. 
 
The EU and its Member States firmly believe that the UNGASS 2016 outcome 
document should be a concise, yet comprehensive document, providing action-oriented 
recommendations towards the goals set in the 2009 Political Declaration and Plan of 
Action for 2019.  
 
The EU and its Member States believe that the outcome of UNGASS 2016 should be 




1. Relying on decades of experience with drug policies based upon an integrated, 
balanced and evidence-based approach, the EU and its Member States emphasise 
that drug policies have proved to be most effective when they strike an appropriate 
balance, in a coordinated manner, between supply and demand reduction 
measures. A drugs policy which does not combine evidence-based and integrated 
demand reduction with targeted actions to restrict supply will neither address the 
objectives set out in the Political Declaration 2009 and Plan of Action for 2019 nor 
tackle the remaining challenges in dealing with the world drug problem. 
2. We underline that drug policies should be built upon a sound public health 
approach, based on scientific evidence and supported by reliable and objective 
monitoring systems and evaluation, in compliance with human rights recognized 
as such by international legal instruments. 
 
International legal framework of the global response to the world drug problem 
 
1. The three UN Drug Control Conventions, which provide the international legal 
framework for addressing the drugs phenomenon, and the Universal Declaration 
on Human Rights are the cornerstones of the global response to the world drug 
problem. While recognizing that drug-related issues are of cross-cutting nature and 
cannot be solved by a single approach or through a predetermined set of policies, 
the EU and its Member States reiterate that the drug control treaties must be 
acknowledged and respected in developing and implementing national drug 
policies and laws, as well as regional and international programs. 
2. We maintain a strong and unequivocal commitment to the UN conventions. There 
is sufficient scope and flexibility within the provisions of the UN Conventions to 
accommodate a wide range of approaches to drug policy in accordance with 
national and regional specificities.  
3. Local, national and international initiatives of developing innovative approaches 
aiming to achieve experience- and evidence-based knowledge in order to attain a 
measurable reduction in illicit supply and demand of drugs as well as in drug-
related harm, should be welcomed and promoted, provided these initiatives are 
undertaken in line with the principles of an integrated and balanced strategy to 
counter the drug problem, international law and common and shared 
responsibility. 
4. The UNGASS should provide guidance on how the efforts to address the 
international drugs phenomenon could be incorporated in a clearer way in the 
work of relevant UN agencies, funds and programs. In the context of the Agenda 
2030 for Sustainable Development, and notably its goals 3 and 16, a holistic 
approach is required to address effectively the world drug problem.   
Human Rights 
 
5. Human rights, including the right to the enjoyment of the highest attainable 
standard of physical and mental health, are an integral part of the international 
response to the world drug problem, in line with the key objective of the UN drug 
control conventions to protect health and welfare of mankind.  
6. The EU and its Member States are opposed to the death penalty in all 
circumstances, including for drug-related offences, and reiterate that the death 
penalty undermines human dignity, while failing to act as deterrent to criminal 
behaviour. The abolition of the death penalty in all circumstances, including for 
drug-related crimes, as well as the abolition of other practices which are not in line 
with the principles of human dignity, liberty, democracy, equality, solidarity, the 
rule of law and human rights, is an absolute priority. Independently of the EU's 
principled opposition to the death penalty, the application of the death penalty for 
drug-related crimes does not meet the threshold of the most serious crimes as in 
Art. 6 (2) of the International Covenant on Civil and Political Rights (ICCPR). 
7. The EU and its Member States call upon States Parties and international 
organisations which provide finance, equipment, training and intelligence to law 
enforcement units of States that continue to apply the death penalty for drug-
related offences, to advocate, within the framework of this cooperation and their 
bilateral dialogue, for enhanced human rights protection and the effective 
implementation of a moratorium on executions, as a first step towards the abolition 
of the death penalty. 
8. The right of the drug user to give an informed consent to treatment should be the 
paramount principle guiding States Parties in the implementation of drug 
dependence treatment programmes and informed consent should be sought as soon 
as possible. Exceptions should be envisaged only in exceptional circumstances 
presenting high risk for oneself and others; even in those cases the treatment 
should nonetheless follow human rights, ethical and scientific standards as for 
voluntary-based treatment.  
9. We invite States Parties within the framework of their national legal systems and 
in compliance with international law and standards, notably the international 
recommendations for proportionality, to develop and implement, when 
appropriate, alternatives to incarceration and coercive sanctions applicable to 
persons having committed minor, non-violent drug-related offences. 
 
The role of civil society in global drugs policy 
 
10. The EU and its Member States attach great importance to the role of civil society 
and the scientific community, in formulating, implementing, monitoring and 
evaluating drug policies at local, national and international level, especially in the 
field of drug demand reduction, and believe that a meaningful and participatory 
role should be recognized for civil society in international drugs policy. In this 
context, the experience of individuals and groups affected by the use of illicit 
drugs should be taken into account. 
 
Demand reduction and related measures, including prevention and treatment, as 
well as health-related issues 
 
11. The EU and its Member States believe that effective, targeted, multidisciplinary 
and evidence-based drug demand reduction policies should include prevention, 
early detection and intervention, risk and harm reduction, treatment, rehabilitation, 
social reintegration and recovery, and build upon continuity of service delivery. 
12. The EU considers that prevention in all its forms and based on thorough need 
assessments  constitutes an integral pillar of any effective drugs strategy. There is 
a need to improve the availability and effectiveness of evaluated and evidence-
based prevention measures to achieve a reduction in demand among the general 
public and in various settings and target groups.  
13. Noting that the key objective of the international drug control system is the 
protection of public health, we emphasise that dependant drug users should be first 
and foremost considered as people in need of attention, care and treatment in order 
to improve their health condition and enhance social integration, tackling 
marginalization and stigmatization. 
14. In this context, States Parties should make sure that access to risk and harm 
reduction measures is guaranteed, as such measures have proved effective in 
reducing the number of direct and indirect drug-related deaths and notably blood-
borne infectious diseases associated with drug use. The technical guidance issued 
by the World Health Organisation (WHO), United Nations Office on Drugs and 
Crime (UNODC) and UNAIDS is of particular relevance in this context 
Access and availability of drug demand reduction measures 
 
15. We urge States Parties to make drug demand reduction measures and drug 
dependence treatment offers accessible, without discrimination, to all members of 
society, including the most vulnerable members, in order to guarantee broad 
availability, coverage and access. 
16. The EU and its Member States consider it essential that all those who need drug 
treatment, including offenders dependent on drugs, receive high quality care. This 
can contribute to their recovery from substance use disorders and reduce the 
likelihood of future illegal activities. Treatment should include both medical and 
non-medical treatment options, be tailored to the individual needs of drug users 
and respond to new patterns of use. 
17. Concerned about the remaining restrictions on the availability of opioid 
substitution treatment in some parts of the world, we consider that access to such 
treatment needs to be increased given its evidence-based efficiency. 
18. We also note that access to drug treatment services and other health care measures 
in prison as well as the diversity and coverage of drug demand reduction measures 
in prison settings need to be substantially improved. Guaranteeing continuity of 
treatment to drug users during imprisonment and after release is essential to 
achieve a quality of care equivalent to that provided in the community. 
Availability of controlled substances for medical and scientific purposes 
 
19. The underlying principles of the international drug control treaties allow ensuring 
the adequate availability of narcotic drugs and psychotropic substances for 
medical and scientific requirements while preventing their inappropriate use and 
abuse. In this context, the EU and its Member States stress the important roles of 
the WHO, the International Narcotics Control Board (INCB), and the UNODC in 
improving access to and availability of these substances and propose that specific 
recommendations to achieve this aim should be agreed at UNGASS.  
20. As regards psychoactive substances with proven legitimate medical or scientific 
use, a thorough and careful assessment, on a case by case basis, is crucial before a 
decision on international control measures under the UN convention is taken, with 
a view of avoiding undue restrictions on legitimate use of such substances. The 
international scheduling of substances at the Commission on Narcotic Drugs 
(CND) should prioritize scientific evidence provided by the WHO 
recommendations, in order to ensure that scheduling decisions do not undermine 
public health objectives.  
 
Supply Reduction and related measures 
 
21. Drug supply reduction measures should be led by a multidisciplinary approach and 
based upon effective coordination of drug-related policies in support of the 
objective of a balanced approach. Improving public safety, while bearing in mind 
public health aspects, should guide criminal justice policies, preventing and 
reducing violence and other harmful consequences. 
22. In accordance with national and international legal frameworks, international 
cooperation needs to be strengthened in order to identify, disrupt and dismantle 
transnational organised criminal groups involved in any illicit activities relating to 
drugs trafficking, including money laundering and corruption. To this end, 
implementation of law enforcement and judicial cooperation mechanisms, as well 
as mutual legal assistance instruments applicable to drug trafficking and related 
crimes could be promoted, while ensuring that the strengthening of international 
cooperation is in accordance with international human rights standards.  
23. A continued commitment to develop collaborative and comprehensive capacities 
to counter the challenges posed by new and existing drug trafficking routes and 
new technologies and methods used by traffickers, is required. Intelligence-
sharing, the strengthening of the international counter-narcotics and border control 
capacities and closer cooperation between existing law enforcement platforms 
should be promoted in this regard. Supply reduction strategies should build upon 
monitoring systems capable of assessing the magnitude of the drug market, new 
threats and developments and measuring the effects and achievements of drug 
supply reduction efforts. 
24. While primarily focusing on individuals and organisations with a significant or 
controlling role in drug trafficking activities, supply reduction efforts should also 
include preventive measures which help addressing the vulnerabilities that drive, 
enable and perpetuate organised crime. 
25. In addition, the full implementation of the United Nations Convention against 
Transnational Organized Crime (UNTOC) and its three Protocols as well as the 
United Nations Convention against Corruption is needed. 
26. The approximation of national legal provisions in order to improve judicial 
cooperation mechanisms, mutual legal assistance and law enforcement instruments 
applicable to drug trafficking and related crimes should be encouraged and 
promoted where appropriate. 
27. Particular attention should be paid to the spreading and diversification of 
precursors chemicals and their substitutes or alternative chemicals used to replace 
traditional precursors under international control. To this end, a better 
implementation of the existing legal provisions, stemming from the requirements 
set out in the 1988 United Nations Convention, and an increased use of the 
available tools should be pursued in order to prevent the diversion of these 
substances. Interagency cooperation and cooperation with the industrial sector are 
essential for an effective control and should thus be further strengthened.  
Alternative development 
 
28. The EU and its Member States promote alternative development, including, where 
appropriate, preventive alternative development, as a long term and holistic 
approach to tackle the root causes and framework conditions of illicit cultivation 
of drug crops, such as poverty, poor infrastructure, limited access to sales market 
for licit products or the weakness of the rule of law. As long as these root causes 
of illicit cultivation of drug crops in rural producing areas persist, the sustainability 
and effects of any supply side intervention will be undermined.  
29. Alternative development has the overall goal to establish viable economic 
alternatives to prohibited cultivation of crops in source countries. These economic 
alternatives should be developed and implemented in close cooperation with local, 
national and international actors, as well as allowing for the monitoring and 
evaluation of the efficiency of these policies.  
30. Acknowledging that the efforts and funds designated to alternative development 
since 2009 have been insufficient, the EU and its Member States consider that 
States Parties should be encouraged to significantly increase long-term investment 
in sustainable crop control strategies targeting the illicit cultivation of crops in 
order to contribute to the sustainability of social and economic development and 
poverty eradication, while reinforcing related supply side interventions. 
 
Drugs Policy and Children, Youth and Women 
 
31. Emphasizing the need “to protect children from the illicit use of narcotic drugs 
and psychotropic substances”, as indicated in article 33 of the Convention on the 
Rights of the Child, the EU and its Member States believe that access for young 
people to adequate evidence-based substance use disorder treatment tailored to 
their specific needs must be ensured, while developing and implementing 
appropriate prevention strategies aimed at the protection of children and young 
people from drug use and related harm. 
 
 
32. Addressing the issues of gender aspects of drug policy and its health consequences 
deserves more attention worldwide. When implementing the Political Declaration 
2009 and Plan of Action for 2019, it is important to recognize that men and 
women are affected in different ways by drug use and drug policies, and take into 
account these aspects in the international efforts to counter the world drug 
problem. 
 
New challenges, threats and realities in preventing and addressing the world drug 
problem 
33. New psychoactive substances being one of the emerging and common challenges 
for drugs policy, States Parties are encouraged to cooperate more closely to 
address this shared problem. This includes supporting the UNODC Early Warning 
Advisory on New Psychoactive Substances, which should be further developed 
and strengthened as a global tool for information sharing, by encouraging 
information exchange and synergies with regional warning systems such as the 
European Early Warning System on NPS, and by providing data to the WHO to 
support evidence-based assessments of substances for international control, as well 
as improving law enforcement cooperation, such as the International Narcotics 
Control Board’s Project ION, with a view of restricting the supply of these 
substances. 
34. Information exchange on effective prevention, treatment and legislative responses 
to this threat to promote a balanced, evidence-based response is also required. 
35. The EU and its Member States are convinced that the international community 
needs to address proactively the role of new communication technologies, such as 
the Internet or the Darknet, in order to efficiently phase out marketing, trafficking 
and distribution of illicit drugs and new psychoactive substances on the Net. In 
that context, the EU and its Member States encourage all States Parties to enhance 
international cooperation in tackling this new challenge. 
36. The European Union and its Member States remain firmly committed to providing 
further input in preparation for UNGASS 2016 to ensure a successful UNGASS 
2016. 
_____________ 
